Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Xenon Pharmaceuticals Inc. (XENE) had Income from Continuous Operations of $-234.33M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-234.33M |
|
-- |
|
-- |
|
$279.30M |
|
$-279.30M |
|
$40.88M |
|
$-238.42M |
|
$-238.42M |
|
$-234.33M |
|
|
Income from Continuous Operations |
$-234.33M |
$-234.33M |
|
$-234.33M |
|
$-279.30M |
|
$-276.74M |
|
77.89M |
|
77.89M |
|
$-3.01 |
|
$-3.01 |
|
| Balance Sheet Financials | |
$635.26M |
|
$10.28M |
|
$162.88M |
|
$798.14M |
|
$35.59M |
|
-- |
|
$7.65M |
|
$43.24M |
|
$754.90M |
|
$754.90M |
|
$754.90M |
|
76.42M |
|
| Cash Flow Statement Financials | |
$-181.39M |
|
$165.00M |
|
$12.13M |
|
$148.64M |
|
$142.71M |
|
$-5.93M |
|
$50.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-184.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.04% |
|
-31.04% |
|
-29.36% |
|
-31.04% |
|
$9.88 |
|
$-2.37 |
|
$-2.33 |
|